A group of undergraduate researchers from Dundee University are the proud recipients of 3 prizes from a conference in Boston, Massachusetts for their breakthrough work on harnessing a fluorescent bacteria to detect a potentially dangerous lung infection in cystic fibrosis (CF) patients. “The Lung Ranger,”…
News
All over the country and throughout the world, local communities organize events to raise both awareness and funds to help patients suffering with cystic fibrosis (CF), as well as to support research dedicated to finding a cure for the life-threatening genetic disease. Approximately 70,000 people suffer from CF worldwide, 30,000 of which…
In a recent study entitled “Subnanometre-resolution electron cryomicroscopy structure of a heterodimeric ABC exporter” published in the online issue of Nature, the authors determined the structure of an ABC transporter protein with a sub nanometer resolution for the first time. The new findings has implications in…
Proteostasis Therapeutics, a company developing novel therapeutics for Cystic Fibrosis and other diseases to address defects in protein folding, trafficking and clearance, and Astellas Pharma Inc. (“Astellas”), a company dedicated to improving people’s health by providing innovative and reliable pharmaceuticals, announced a worldwide joint collaboration to research and…
Massachusetts-based Vertex Pharmaceuticals, Inc. announced yesterday that they have filed for a New Drug Application (NDA) with the US Food and Drug Administration, and a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for their pipeline combination lumacaftor–ivacaftor drug, indicated for the…
A recent study entitled “Stochastic Tracking of Infection in a CF Lung” presents a new algorithm that improves recorded imaging results for examining the lungs of Cystic Fibrosis patients by providing information at a microscopic level of the infection site. This study was published on PlosOne…
Developmental stage biopharmaceutical company Parion Sciences recently announced that the National Institutes of Health‘s grants over the next 5 years in support of pulmonary research programs using their novel pipeline treatments will reach a total of about $15.6 million. These grants have gone to the University of North Carolina,…
Australian specialist pharmaceutical company Pharmaxis has just announced it has successfully enrolled the first participant in an international Phase 3 clinical trial designed to evaluate their lead pipeline product for cystic fibrosis, Bronchitol® (mannitol). Pharmaxis continues to develop novel treatments for chronic respiratory disorders, such as asthma, pulmonary…
A new study on the impact of Cystic Fibrosis carrier status in in vitro fertilization (IVF) procedures and outcomes, entitled “Female cystic fibrosis mutation carriers and assisted reproductive technology: Does carrier status affect reproductive outcomes?“ was recently announced by Celmatix, a New York City-based company…
Santa Fe, New Mexico based startup Avisa Pharma Inc. is a clinical stage company established in 2010 to develop and commercialize a new technology invented by Dr. Graham Timmins, Avisa’s Co-founder/Chief Science Officer and a University of New Mexico College of Pharmacy Associate Professor, who was assisted by colleagues from UNM’s School…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.